XOMA Ltd. is a biopharmaceutical company focused on the discovery, development and manufacture of therapeutic antibodies. XOMA uses its expertise, technologies and capabilities to build a product pipeline that includes multiple collaborative development programs. The Company receives royalties on two approved products, Raptiva, which is marketed globally for the treatment of moderate-to-severe plaque psoriasis, and Lucentis, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration. XOMA has established on-going technology licensing programs for certain of its technologies, which have attracted licensees including Pfizer, Inc. The Company’s development collaborations include arrangements with Novartis AG, Schering Plough Research Institute (SPRI) and Takeda Pharmaceutical Company Limited.
(Source: 10-K) – less – More from ZoomInfo »